← Back to home

NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER)

Clinical trials for NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) explained in plain language.

Never miss a new study

Get alerted when new NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) trials appear

Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New combo tackles tough lung cancer

Disease control Ongoing

This early-phase trial is testing whether adding the immunotherapy drug ipilimumab (Yervoy) to the targeted therapy osimertinib (Tagrisso) is safe and tolerable for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study involves 2…

Matched conditions: NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER)

Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control

Last updated Jun 23, 2026 23:34 UTC

NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER)

Get alerted when new NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) trials appear

New combo tackles tough lung cancer